Table II.
Antithrombotic medication | Overall (N = 2122), n (%) | 65-79 y (n = 1645), n (%) | ≥80 y (n = 477), n (%) |
---|---|---|---|
No aspirin, clopidogrel, or warfarin | 254 (12.0) | 209 (12.7) | 45 (9.4) |
Aspirin or clopidogrel alone* | 477 (22.5) | 372 (22.6) | 105 (22.0) |
Aspirin and clopidogrel | 566 (26.7) | 415 (25.2) | 151 (31.7) |
Warfarin alone | 83 (3.9) | 62 (3.8) | 21 (4.4) |
Warfarin + (aspirin or clopidogrel)† | 590 (27.8) | 478 (29.1) | 112 (23.5) |
Triple therapy | 152 (7.2) | 109 (6.6) | 43 (9.0) |
Antiplatelet therapy alone‡,§ | 1043 (49.2) | 787 (47.8) | 256 (53.7) |
Warfarin and antiplatelet therapy‡,§ | 742 (35.0) | 587 (35.7) | 155 (32.5) |
Any aspirin§ | 1769 (83.4) | 1359 (82.6) | 410 (86.0) |
Any clopidogrel§ | 734 (34.6) | 539 (32.8) | 195 (40.9) |
Any warfarin§ | 825 (38.9) | 649 (39.5) | 176 (36.9) |
Clopidogrel alone used in 15 (0.7%) patients overall, 14 (0.9%) patients 65 to 79 years old, and 1 (0.2%) patient ≥80 years old.
Warfarin + clopidogrel used in 1 (0.0%) patient overall and 1 (0.1%) patient 65 to 79 years old.
Antiplatelet therapy defined as aspirin, clopidogrel, or both.
Categories within each division are not mutually exclusive.